nafamostat has been researched along with sepimostate mesilate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Fuwa, M; Kageyama, M; Ohashi, K; Sasaoka, M; Sato, R; Tanaka, M; Tashiro, K | 1 |
1 review(s) available for nafamostat and sepimostate mesilate
| Article | Year |
|---|---|
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
1 other study(ies) available for nafamostat and sepimostate mesilate
| Article | Year |
|---|---|
Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model.
Topics: Animals; Benzamidines; Cell Death; Cerebral Cortex; Excitatory Amino Acid Antagonists; Guanidines; Imidazoles; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Retinal Degeneration | 2019 |